Haematologica (Feb 2011)

Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host

  • Hugues de Lavallade,
  • Paula Garland,
  • Takuya Sekine,
  • Katja Hoschler,
  • David Marin,
  • Kate Stringaris,
  • Eva Loucaides,
  • Katherine Howe,
  • Richard Szydlo,
  • Ed Kanfer,
  • Donald Macdonald,
  • Peter Kelleher,
  • Nichola Cooper,
  • Ahmad Khoder,
  • Ian H. Gabriel,
  • Dragana Milojkovic,
  • Jiri Pavlu,
  • John M. Goldman,
  • Jane F. Apperley,
  • Katayoun Rezvani

DOI
https://doi.org/10.3324/haematol.2010.032664
Journal volume & issue
Vol. 96, no. 2

Abstract

Read online

Background In 2009 the declaration by the World Health Organization of a global pandemic of influenza-H1N1 virus led to a vaccination campaign to ensure protection for immunocompromised patients. The goal of this study was to determine the efficacy of the 2009 H1N1 vaccine in patients with hematologic malignancies.Design and Methods We evaluated humoral and cellular immune responses to 2009 H1N1 vaccine in 97 adults with hematologic malignancies and compared these responses with those in 25 adult controls. Patients received two injections of vaccine 21 days apart and the controls received one dose. Antibody titers were measured using a hemagglutination-inhibition assay on days 0, 21 and 49 after injection of the first dose. Cellular immune responses to H1N1 were determined on days 0 and 49.Results By day 21 post-vaccination, protective antibody titers of 1:32 or more were seen in 100% of controls compared to 39% of patients with B-cell malignancies (P